- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06876584
The CT-based Deep Learning Model Predicts Complications in Partial Nephrectomy
The CT-based Deep Learning Model Outperforms Traditional Anatomical Classification Models in Preoperatively Predicting Complications and Risk Grade in Partial Nephrectomy
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Xuhui District
-
Shanghai, Xuhui District, China, 200032
- Name: Zhongshan Hospital Fudan University, Location: 180th Fenglin Road, Xuhui District, Shanghai, China
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
The study population includes patients diagnosed with renal cell carcinoma or renal cyst who underwent partial nephrectomy in the participated centers. Clinical and imaging data were retrospectively collected from medical records, including demographic characteristics (age, gender, BMI), tumor location (left or right kidney), surgical details (surgical approach, ischemia time), and perioperative complications.
Patients were included based on the availability of complete clinical, surgical, and imaging data. Exclusion criteria comprised individuals with missing or unavailable imaging data, or no available enhanced CT images. The study aims to combine CT-based radiomics features and clinical features to develop a deep learning model to predict perioperative complications of partial nephrectomy, and compare with traditional anatomical classification models.
Description
Inclusion Criteria:
- Clinical diagnosis of renal cell carcinoma or renal cyst
- Underwent partial nephrectomy between June 2014 and July 2024
Exclusion Criteria:
- Missing or unavailable imaging data
- No available enhanced CT images
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Complication 1
Patients who experienced perioperative complications during the partial nephrectomy
|
|
Complication 0
Patients who didn't experience perioperative complications during the partial nephrectomy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
whether complications occurred
Time Frame: perioperatively
|
Retrospectively review the medical record system to determine whether patients developed postoperative complications.
|
perioperatively
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patients' risk grade
Time Frame: perioperatively
|
Based on the widely recognized Clavien-Dindo classification (CDC) system for surgical complications, these complications were categorized into four grades: Grade I, II, III, and IV.
Risk grade was assigned accordingly: "no risk" is defined as no complications occurred, "grade low" is defined as the highest level of complication being Grade I, "grade moderate" is defined as the highest level of complication being Grade II, and "grade high" is defined as complications of Grade III or higher, which are life-threatening.
|
perioperatively
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Neoplasms by Histologic Type
- Neoplasms, Glandular and Epithelial
- Adenocarcinoma
- Urologic Neoplasms
- Carcinoma
- Kidney Neoplasms
- Carcinoma, Renal Cell
Other Study ID Numbers
- zsurologyDLMforPNcomplication
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Cell Carcinoma (RCC)
-
Cancer Institute and Hospital, Chinese Academy...Not yet recruitingAtorvastatin | PTC | Advanced Renal Cell Carcinoma (RCC) | Targeted Therapy Combined With ImmunotherapyChina
-
Guru SonpavdePfizer; Hoosier Cancer Research NetworkWithdrawnKidney Cancer | Clear-cell Renal Cell Carcinoma | RCC | Clear-cell Kidney CarcinomaUnited States
-
Neomorph, IncRecruitingRenal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | Kidney Cancer Metastatic | ccRCC | RCC | VHL-Associated Renal Cell Carcinoma | VHL-Associated Clear Cell Renal Cell Carcinoma | Clear Cell Renal Cell Carcinoma Metastatic | Kidney CancersUnited States
-
Ludwig Institute for Cancer ResearchPfizer; Heidelberg Pharma AGTerminatedRenal Cell Carcinoma (RCC)Australia
-
Fox Chase Cancer CenterTerminatedMetastatic Renal Cell Carcinoma | RCCUnited States
-
Ludwig Institute for Cancer ResearchMemorial Sloan Kettering Cancer CenterCompletedKidney Cancer | Clear Cell Renal Cell Carcinoma | Renal Cancer | Renal Cell Carcinoma (RCC) | Renal Neoplasms | Cancer of Kidney | Neoplasms, KidneyUnited States
-
Sun Yat-sen UniversityEnrolling by invitationMetastatic Clear Cell Renal Cell Carcinoma | Renal Cell Carcinoma (RCC)China
-
Celldex TherapeuticsTerminatedKidney Neoplasms | Metastatic Renal Cell Carcinoma | Ovarian Clear Cell Carcinoma | Papillary Renal Cell Carcinoma | Renal Cell Carcinoma (RCC) | Clear-cell Renal Cell CarcinomaUnited States
-
Novartis PharmaceuticalsCompletedCancer | Renal Cell Carcinoma (RCC)United States, Belgium, Canada, Spain, United Kingdom, Turkey, Austria, Argentina, Brazil, Czechia, France, Germany, Israel, Italy, Poland, Russian Federation, Korea, Republic of, Chile, China, Greece, Hungary, Ireland, Slovakia, Japan, Denmar... and more
-
Peloton Therapeutics, Inc., a subsidiary of Merck...Active, not recruitingA Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)Kidney Cancer | Clear Cell Renal Cell Carcinoma | Glioblastoma | Solid Tumor | Glioblastoma Multiforme | Advanced Solid Tumors | GBM | Solid Tumor, Adult | Solid Carcinoma | Glioblastoma, Adult | ccRCC | RCC, Clear Cell Adenocarcinoma | RCC | Renal Cell Carcinoma, Metastatic | Renal Cell Carcinoma Recurrent | Renal Cell...